SCHEMBL317537

SCHEMBL317537

Fc1cccc2c(Cl)ccnc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.53
ALDH1A1 P00352 5/20 0.53
TDP1 Q9NUW8 5/20 0.53
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
LMNA P02545 4/20 0.47
MAPT P10636 4/20 0.47
HSP90AA1 P07900 3/20 0.47
METAP2 P50579 2/20 0.47
METAP1 P53582 2/20 0.47
NR4A2 P43354 1/20 0.47
BRD4 O60885 1/20 0.47
MMP14 P50281 3/20 0.46
CYP3A4 P08684 3/20 0.46
ALOX12 P18054 3/20 0.46
HTT P42858 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 2/20 0.46
ALOX15 P16050 2/20 0.46
SLC6A2 P23975 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543147 1.00 KDM4E (0.53) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL318769 0.81 NR4A2 (0.68) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL29410781 0.81 NR4A2 (0.68) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL6615706 0.76 NR4A2 (0.61) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL317120 0.76 HTR1A (0.56) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL3630037 0.76 KDM4E (0.53) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL1245479 0.76 KDM4E (0.54) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL19983428 0.76 PSMD14 (0.47) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL2701957 0.76 KDM4E (0.72) KDM4EALDH1A1TDP1MEN1KMT2A
SCHEMBL2515670 0.76 NR4A2 (0.61) KDM4EALDH1A1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 US disclosed
US-12611404-B2 Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides CHEMOCENTRYX, INC. (US) 2026-04-28 US disclosed
WO-2025090465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-05-01 WO disclosed
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 US disclosed
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-26 US disclosed
EP-4214199-A1 CASEIN KINASE 1 DELTA MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-07-26 EP disclosed
CN-116490503-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-07-25 CN disclosed
WO-2022235091-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF 엠비디 주식회사 2022-11-10 WO disclosed
US-5294622-A Fungicides, insecticides, miticides DOWELANCO (US) 1994-03-15 US disclosed
WO-1994004526-A1 4-[2-(4-(2-PYRIDINYLOXY)PHENYL)ETHOXY]-QUINAZOLINE AND ANALOGUES THEREOF DOWELANCO (US) 1994-03-03 WO disclosed
WO-1993005050-A1 4-(ARALKOXY OR ARALKYLAMINO)PYRIDINE PESTICIDES_________________ DOWELANCO (US) 1993-03-18 WO disclosed
US-5114939-A Amine or ether substitutes compounds of quinoline or cinnoline DOWELANCO (US) 1992-05-19 US disclosed
EP-0326331-A2 Substituted quinolines and cinnolines DowElanco (US) 1989-08-02 EP disclosed
EP-0326328-A2 Quinoline, quinazoline, and cinnoline derivatives DowElanco (US) 1989-08-02 EP disclosed
EP-0168812-A1 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1986-01-22 EP disclosed
EP-0001175-A1 4-Aminoquinoline derivatives, a process for their preparation and pharmaceutical compositions containing them JOHN WYETH & BROTHER LIMITED (GB) 1979-03-21 EP disclosed
US-4057633-A ANTIANXIETY, HYPOTENSIVE THE UPJOHN COMPANY (US) 1977-11-08 US disclosed
US-3992382-A HYPERTENSION AND ANXIETY TREATMENT THE UPJOHN COMPANY (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF CYP4B1, CYP4A11, CYP3A4 KDM4E 642/4885ALDH1A1 268/4885TDP1 3057/4885
US-20230339900-A1 CASEIN KINASE 1 DELTA MODULATORS CSNK1D, CSNK1A1, CSNK2A1 KDM4E 2449/4885ALDH1A1 1600/4885TDP1 1173/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 KDM4E 1396/4885ALDH1A1 217/4885TDP1 1533/4885
US-12611404-B2 Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides CCR1, CCR9, CCR8 KDM4E 2895/4885ALDH1A1 2034/4885TDP1 4614/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 KDM4E 3526/4885ALDH1A1 2543/4885TDP1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.